Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Gilead outlays $5bn to acquire ADC specialist Tubulis

 April 7, 2026

Pharmaceutical Technology

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

M&A / DealsRead full story

Post navigation

Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis →
← Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com